Dr. Stanley R. Riddell is a full member of the Program in Immunology of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, and a professor of Oncology at the University of Washington.
Dr. Riddell is an expert in cell transplantations and T cell-based immunotherapies, and has used them to treat many patients with lymphoma and leukemia. He’s contributed many advances that are widely used in cell-based immunotherapy approaches, including CAR T cells, and also led the first clinical trial that utilized adoptively transferred T cells. He has been elected to the Association of American Physicians, and his current work builds on his previous accomplishments and seeks to identify further ways to improve the effectiveness of T cell immunotherapies.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. Riddell serves on the CLIP Grant Review Committee.
We are entering … a new era where immunotherapy is going to become as established as surgery, radiation and chemotherapy, and I’m hoping that it’s going to be a lot safer for patients and a lot more effective.
Let's spread the word about Immunotherapy! Click to share this page with your community.